Ads
related to: stopping statins and heart attack patients- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Trial Results
See Clinical Data
and Trial
- Co-Pay Program
Resources
to Support Your Patients
- Request Samples
Get patients started
with a 14-day sample
- Dosing & Administration
nexlizet.com has been visited by 100K+ users in the past month
wexnermedical.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Statins and heart disease in brief. ... people who have already suffered a cardiovascular event such as heart attack or stroke, ... if we recommend they stop taking statins, they still could be ...
These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
The trial analyzed 17,802 patients without evidence of heart disease but with high CRP levels. In 2008, results presented at the American Heart Association meeting and published in the New England Journal of Medicine (NEJM) found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had a lower rate of major cardiovascular events.
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol and heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%. [12] [191] In 1995, Zocor and Mevacor both made Merck over US$1 ...
Ad
related to: stopping statins and heart attack patients